Article Text

PDF
High serum soluble α-Klotho levels in patients with autosomal dominant polycystic kidney disease
  1. Funda Sari1,
  2. Ayca Inci2,
  3. Suleyman Dolu2,
  4. Hamit Yasar Ellidag3,
  5. Ramazan Cetinkaya1,
  6. Fettah Fevzi Ersoy1
  1. 1Division of Nephrology, Department of Internal Medicine, Akdeniz University, Antalya, Turkey
  2. 2Department of Internal Medicine, Antalya Training and Research Hospital, Antalya, Turkey
  3. 3Department of Biochemistry, Antalya Training and Research Hospital, Antalya, Turkey
  1. Correspondence to Dr Funda Sari, Akdeniz University, School of Medicine, Division of Nephrology, Antalya, Turkey; fundasari{at}ymail.com

Abstract

This study aims to determine fibroblast growth factor-23 and soluble α-Klotho levels in patients with autosomal dominant polycystic kidney disease. A total of 76 patients with autosomal dominant polycystic kidney disease and 32 healthy volunteers were included in the study. Serum fibroblast growth factor-23 and soluble α-Klotho levels were measured with ELISA kits. Parathyroid hormone, phosphate, calcium, creatinine, 25-hydroxyvitamin D3 levels, urinary protein to creatinine ratio and estimated glomerular filtration rate were also measured or calculated. Patients with autosomal dominant polycystic kidney disease had significantly higher serum parathyroid hormone (p<0.001), fibroblast growth factor-23 (p<0.001), soluble α-Klotho levels (p=0.001) and lower serum 25-hydroxyvitamin D3 levels (p<0.001) as compared with healthy volunteers. Serum fibroblast growth factor-23, soluble α-Klotho and 25-hydroxyvitamin D3 levels were similar in all five chronic kidney disease stages of autosomal dominant polycystic kidney disease (p>0.05). Fibroblast growth factor-23 (r=−0.251, p=0.034) and soluble α-Klotho levels (r=−0.251, p=0.034) were found to be negatively correlated with estimated glomerular filtration rate. This study shows increased fibroblast growth factor-23 levels in patients with autosomal dominant polycystic kidney disease which is in harmony with the general trend in patients with chronic kidney disease of other aetiologies, but, unlike them, also a significant increase in serum soluble α-Klotho levels in patients with autosomal dominant polycystic kidney disease suggesting an aberrant production or a decreased clearance of α-Klotho molecule. Considering the unique increases in erythropoietin levels due to erythropoietin production in renal cysts, we assume, patients with autosomal dominant polycystic kidney disease may potentially have different soluble α-Klotho production/clearance characteristics than the patients with other parenchymal renal diseases.

  • 25-hydroxyvitamin D
  • Fibroblast Growth Factors
  • Kidney Diseases

Statistics from Altmetric.com

Footnotes

  • Contributors FS and AI were involved in research design and writing. SD and HYE were involved in data collection. RC and FFE were involved in editing.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Ethics approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

  • Provenance and peer review Not commissioned; externally peer reviewed.

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.